| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
Oct 30, 2026 | BUY |
Strong Buy
-6.0% avg upside
18 analysts
|
$500.00
21.14% Upside
|
+1.0% | Β· |
|
TKNO
Alpha Teknova
|
Oct 13, 2026 | BUY |
Strong Buy
+74.1% avg upside
8 analysts
|
$11.00
49.43% Upside
|
+6.6% | Β· |
|
HALO
Halozyme
|
Oct 13, 2026 | BUY |
Strong Buy
-48.1% avg upside
20 analysts
|
$130.00
0.76% Downside
|
-8.5% | Β· |
|
CERT
Certara
|
Oct 13, 2026 | BUY |
Buy
+21.4% avg upside
23 analysts
|
$11.00
0.17% Downside
|
+22.2% | Β· |
|
SDGR
Schrodinger
|
Oct 13, 2026 | BUY |
Buy
+7.1% avg upside
16 analysts
|
$31.00
14.12% Upside
|
+12.9% | Β· |
|
TWST
Twist Bioscience
|
Oct 13, 2026 | BUY |
Strong Buy
-19.2% avg upside
16 analysts
|
$190.00
24.38% Upside
|
-24.7% | Β· |
|
DNA
Ginkgo Bioworks Holdings
|
Oct 13, 2026 | HOLD |
Strong Sell
-32.3% avg upside
6 analysts
|
$11.00
1.88% Downside
|
-12.8% | Β· |
|
MRVI
Maravai Lifesciences Holdings
|
Oct 05, 2026 | BUY |
Strong Buy
+99.5% avg upside
18 analysts
|
$9.00
15.21% Upside
|
-11.5% | Β· |
|
ABSI
AbSci
|
Sep 30, 2026 | BUY |
Strong Buy
+20.1% avg upside
20 analysts
|
β | -22.0% | Β· |
|
OABI
OmniAb
|
Aug 17, 2026 | BUY |
Strong Buy
+59.0% avg upside
10 analysts
|
$5.00
2.15% Downside
|
+33.5% | Β· |
|
MXCT
MaxCyte
|
Aug 13, 2026 | BUY |
Strong Buy
+151.6% avg upside
5 analysts
|
β | -18.0% | Β· |
|
CDXS
Codexis
|
Aug 11, 2026 | HOLD |
Strong Buy
+746.4% avg upside
13 analysts
|
$2.00
68.11% Upside
|
-21.6% | Β· |
|
MASS
908 Devices
|
Aug 11, 2026 | BUY |
Strong Buy
+11.1% avg upside
5 analysts
|
β | +15.0% | Β· |
|
PASG
Passage Bio
|
Aug 10, 2026 | HOLD |
Buy
+407.3% avg upside
14 analysts
|
β | -20.6% | Β· |
|
CTKB
Cytek Biosciences
|
Aug 05, 2026 | HOLD |
Buy
-4.2% avg upside
5 analysts
|
$5.00
18.48% Downside
|
+38.9% | Β· |
|
RXRX
Recursion Pharmaceuticals
|
Aug 05, 2026 | HOLD |
Buy
+92.7% avg upside
12 analysts
|
β | +1.9% | Β· |
|
ABCL
AbCellera Biologics
|
Aug 05, 2026 | BUY |
Strong Buy
+33.0% avg upside
18 analysts
|
β | +94.1% | Β· |
|
AZTA
Azenta
|
Aug 05, 2026 | HOLD |
Buy
+24.4% avg upside
13 analysts
|
$33.00
15.49% Downside
|
+23.1% | Β· |
|
RGEN
Repligen
|
Jul 28, 2026 | BUY |
Strong Buy
+1.3% avg upside
25 analysts
|
$200.00
13.13% Upside
|
+23.1% | Β· |
|
EVO
Evotec AG
|
Jul 15, 2026 | HOLD |
Buy
+444.5% avg upside
9 analysts
|
$2.00
30.64% Upside
|
-15.9% | Β· |
|
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
|
Jul 14, 2026 | HOLD |
Hold
-92.8% avg upside
1 analyst
|
$2.00
92.80% Downside
|
+3.0% | Β· |
|
RPID
Rapid Micro Biosystems
|
May 27, 2026 | BUY |
Strong Buy
+1089.0% avg upside
6 analysts
|
β | -61.6% | Β· |
|
ARWR
Arrowhead Pharmaceuticals
|
May 13, 2025 | BUY |
Strong Buy
+26.6% avg upside
29 analysts
|
β | +409.7% | Β· |
|
DNLI
Denali Therapeutics
|
May 06, 2025 | BUY |
Strong Buy
+104.7% avg upside
24 analysts
|
β | +46.1% | Β· |
|
NVAX
Novavax
|
Nov 12, 2024 | HOLD |
Buy
+130.1% avg upside
20 analysts
|
$9.00
10.77% Downside
|
-14.9% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.